These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20712480)

  • 1. Characterization of Anti-HCV Antibodies in IL-10-Treated Patients.
    Eksioglu EA; Bess J; Jones G; Dettloff J; Dangmeon P; Dong HJ; Zhu H; Firpi R; Xu Y; Nelson DR; Liu C
    Viral Immunol; 2010 Aug; 23(4):359-68. PubMed ID: 20712480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies.
    Fournier C; Duverlie G; François C; Schnuriger A; Dedeurwaerder S; Brochot E; Capron D; Wychowski C; Thibault V; Castelain S
    Virol J; 2007 Mar; 4():35. PubMed ID: 17397531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mice Antibody Response to Conserved Nonadjuvanted Multiple Antigenic Peptides Derived from E1/E2 Regions of Hepatitis C Virus.
    Abdelhafez TH; Bader El Din NG; Tabll AA; Mashaly MM; Dawood RM; Yassin NA; El-Awady MK
    Viral Immunol; 2017 Jun; 30(5):359-365. PubMed ID: 28402196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C.
    Ishii K; Rosa D; Watanabe Y; Katayama T; Harada H; Wyatt C; Kiyosawa K; Aizaki H; Matsuura Y; Houghton M; Abrignani S; Miyamura T
    Hepatology; 1998 Oct; 28(4):1117-20. PubMed ID: 9755251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of neutralizing antibodies against hepatitis C virus in patients who were treated with pegylated-interferon plus ribavirin.
    Sasayama M; Deng L; Kim SR; Ide Y; Shoji I; Hotta H
    Kobe J Med Sci; 2010 Sep; 56(2):E60-6. PubMed ID: 21063147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of longitudinal change in hepatitis C virus neutralization titers correlate with the outcome of peginterferon and ribavirin combination therapy.
    Lin J; Wang W; Xu Y; Di Bisceglie AM; Fan X
    J Med Virol; 2015 May; 87(5):821-8. PubMed ID: 25652546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kuzuya T; Honda T; Hayashi K; Nakano I; Katano Y; Goto H
    Clin Infect Dis; 2005 Mar; 40(6):e49-54. PubMed ID: 15736006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low cross-neutralization of hepatitis C correlates with liver disease in immunocompromized patients.
    Maurin G; Halgand B; Bruscella P; Fresquet J; Duclos-Vallée JC; Roque-Afonso AM; Cosset FL; Samuel D; Lavillette D; Féray C
    AIDS; 2015 Jun; 29(9):1025-33. PubMed ID: 26125137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibodies in patients with chronic hepatitis C and correlation to liver cirrhosis and estimated duration of infection.
    Pedersen J; Lundbo LF; Krarup H; Bukh J; Weis N
    J Med Virol; 2016 Oct; 88(10):1791-803. PubMed ID: 27027386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
    Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
    J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.
    Rosa D; Campagnoli S; Moretto C; Guenzi E; Cousens L; Chin M; Dong C; Weiner AJ; Lau JY; Choo QL; Chien D; Pileri P; Houghton M; Abrignani S
    Proc Natl Acad Sci U S A; 1996 Mar; 93(5):1759-63. PubMed ID: 8700831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses.
    Shimizu YK; Hijikata M; Iwamoto A; Alter HJ; Purcell RH; Yoshikura H
    J Virol; 1994 Mar; 68(3):1494-500. PubMed ID: 8107212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A point mutation at Asn-534 that disrupts a conserved N-glycosylation motif of the E2 glycoprotein of hepatitis C virus markedly enhances the sensitivity to antibody neutralization.
    Sasayama M; Shoji I; Adianti M; Jiang DP; Deng L; Saito T; Watanabe H; Kawata S; Aoki C; Hotta H
    J Med Virol; 2012 Feb; 84(2):229-34. PubMed ID: 22170542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative analysis of specific Th1/Th2 helper cell responses and IgG subtype antibodies in interferon-alpha-treated patients with chronic hepatitis C.
    Hempel G; Galle PR; Löhr HF
    J Med Virol; 2001 Jul; 64(3):340-9. PubMed ID: 11424124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein.
    Meyer K; Basu A; Przysiecki CT; Lagging LM; Di Bisceglie AM; Conley AJ; Ray R
    J Virol; 2002 Mar; 76(5):2150-8. PubMed ID: 11836392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and associated factors of neutralizing anti-interferon antibodies among chronic hepatitis C patients treated with interferon in Taiwan.
    Hou C; Chuang WL; Yu ML; Dai CY; Chen SC; Lin ZY; Hsieh MY; Wang LY; Tsai JF; Chang WY
    Scand J Gastroenterol; 2000 Dec; 35(12):1288-93. PubMed ID: 11199369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance.
    Merat SJ; Bru C; van de Berg D; Molenkamp R; Tarr AW; Koekkoek S; Kootstra NA; Prins M; Ball JK; Bakker AQ; de Jong MD; Spits H; Beaumont T; Schinkel J
    J Hepatol; 2019 Jul; 71(1):14-24. PubMed ID: 30797052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity.
    Zhang P; Zhong L; Struble EB; Watanabe H; Kachko A; Mihalik K; Virata ML; Alter HJ; Feinstone S; Major M
    Proc Natl Acad Sci U S A; 2009 May; 106(18):7537-41. PubMed ID: 19380744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.